OncoMatch/Clinical Trials/NCT07306624
Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
Is NCT07306624 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Nelmastobart and Docetaxel for non small cell lung cancer.
Treatment: Nelmastobart and Docetaxel — A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: BTN1A1 tps score ≥50 (≥50)
BTN1A1 TPS score ≥50
Disease stage
Required: Stage IIIB, IIIC, IV
stage IIIb, IIIc, or IV recurrent NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Subjects with positive AGA must have progressed after At least 1 platinum-based chemotherapy and/or immunotherapy AND at least 1 locally approved targeted therapy appropriate to the AGA
Must have received: immunotherapy
Subjects with positive AGA must have progressed after At least 1 platinum-based chemotherapy and/or immunotherapy AND at least 1 locally approved targeted therapy appropriate to the AGA
Must have received: targeted therapy
Subjects with positive AGA must have progressed after ... at least 1 locally approved targeted therapy appropriate to the AGA
Must have received: PD-1/PD-L1 inhibitor
Subjects with negative AGA must have progressed after prior PD1/ (PDL therapy and/or at least 1platinum-based chemotherapy
Must have received: platinum-based chemotherapy
Subjects with negative AGA must have progressed after prior PD1/ (PDL therapy and/or at least 1platinum-based chemotherapy
Cannot have received: Docetaxel for palliative therapy (Docetaxel)
History of using Docetaxel for palliative therapy
Lab requirements
Blood counts
Adequate organ function as described in the protocol
Kidney function
Adequate organ function as described in the protocol
Liver function
Adequate organ function as described in the protocol
Cardiac function
Adequate cardiac function as described in the protocol
Adequate organ function as described in the protocol; Adequate cardiac function as described in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07306624 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Docetaxel for palliative therapy disqualifies patients from enrollment.
Does this trial require BTN1A1?
Yes, BTN1A1 tps score ≥50 is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages